143 related articles for article (PubMed ID: 15785771)
1. Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant.
Blijlevens NM; Donnelly JP; de Pauw BE
Bone Marrow Transplant; 2005 Apr; 35(7):707-11. PubMed ID: 15785771
[TBL] [Abstract][Full Text] [Related]
2. Measuring mucosal damage induced by cytotoxic therapy.
Blijlevens NM; van't Land B; Donnelly JP; M'Rabet L; de Pauw BE
Support Care Cancer; 2004 Apr; 12(4):227-33. PubMed ID: 14752625
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients.
Blijlevens NM; Donnelly JP; DePauw BE
Bone Marrow Transplant; 2005 Oct; 36(8):703-7. PubMed ID: 16062174
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.
Hwang WY; Koh LP; Ng HJ; Tan PH; Chuah CT; Fook SC; Chow H; Tan KW; Wong C; Tan CH; Goh YT
Bone Marrow Transplant; 2004 Jul; 34(1):51-6. PubMed ID: 15208650
[TBL] [Abstract][Full Text] [Related]
6. Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients.
Derikx JP; Blijlevens NM; Donnelly JP; Fujii H; Kanda T; van Bijnen AA; Heineman E; Buurman WA
Ann Oncol; 2009 Feb; 20(2):337-42. PubMed ID: 18725393
[TBL] [Abstract][Full Text] [Related]
7. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
[TBL] [Abstract][Full Text] [Related]
8. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
[TBL] [Abstract][Full Text] [Related]
9. Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation.
Caliskan Y; Besisik SK; Sargin D; Ecder T
Bone Marrow Transplant; 2006 Jul; 38(2):141-7. PubMed ID: 16770317
[TBL] [Abstract][Full Text] [Related]
10. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning.
Yoshihara S; Tateishi U; Ando T; Kunitoh H; Suyama H; Onishi Y; Tanosaki R; Mineishi S
Bone Marrow Transplant; 2005 Jun; 35(12):1195-200. PubMed ID: 15852024
[TBL] [Abstract][Full Text] [Related]
11. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation.
Yoshimi A; Nannya Y; Sakata-Yanagimoto M; Oshima K; Takahashi T; Kanda Y; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Aug; 83(8):635-9. PubMed ID: 18506704
[TBL] [Abstract][Full Text] [Related]
12. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group.
Gori E; Arpinati M; Bonifazi F; Errico A; Mega A; Alberani F; Sabbi V; Costazza G; Leanza S; Borrelli C; Berni M; Feraut C; Polato E; Altieri MC; Pirola E; Loddo MC; Banfi M; Barzetti L; Calza S; Brignoli C; Bandini G; De Vivo A; Bosi A; Baccarani M
Bone Marrow Transplant; 2007 Mar; 39(6):347-52. PubMed ID: 17277790
[TBL] [Abstract][Full Text] [Related]
13. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
14. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
[TBL] [Abstract][Full Text] [Related]
15. Gut protection by palifermin during autologous haematopoietic SCT.
Johansson JE; Hasséus B; Johansson P; Eklöf C; Ohman D; Stockelberg D
Bone Marrow Transplant; 2009 May; 43(10):807-11. PubMed ID: 19043460
[TBL] [Abstract][Full Text] [Related]
16. Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.
Narreddy S; Mellon-Reppen S; Abidi MH; Klein JL; Peres E; Heilbrun LK; Smith D; Alangaden G; Chandrasekar PH
Transpl Infect Dis; 2007 Mar; 9(1):3-10. PubMed ID: 17313464
[TBL] [Abstract][Full Text] [Related]
17. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
[TBL] [Abstract][Full Text] [Related]
18. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
[TBL] [Abstract][Full Text] [Related]
19. Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy.
Blijlevens NM; Lutgens LC; Schattenberg AV; Donnelly JP
Bone Marrow Transplant; 2004 Aug; 34(3):193-6. PubMed ID: 15170165
[TBL] [Abstract][Full Text] [Related]
20. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
